Promoting HPV Vaccination Among Young Adults in Texas

N/AActive Not RecruitingNCT05057312

M.D. Anderson Cancer Center1,200 enrolled

Overview

This clinical trial studies how to improve the human papillomavirus (HPV) vaccination rate in young adults in Texas. This trial aims to learn more about how researchers and health care providers can increase HPV vaccination among college students.

PRIMARY OBJECTIVES: I. To determine the impact of addressing individual and system levels of influence on HPV vaccination initiation and completion rates. II. To gain insight into mechanisms of the intervention's efficacy, individual differences, and implementation of the intervention using mixed methods. OUTLINE: Participants are randomized to 1 of 6 groups. GROUP I: Participants receive standard Centers for Disease Control and Prevention (CDC) information about HPV vaccination. GROUP II: Participants receive video narratives about HPV vaccination. GROUP III: Participants receive written narratives about HPV vaccination. GROUP IV: Participants receive enhanced access to vaccination and standard CDC information about HPV vaccination. GROUP V: Participants receive enhanced access to vaccination and video narratives about HPV vaccination. GROUP VI: Participants receive enhanced access to vaccination and written narratives about HPV vaccination. After completion of study, participants are followed up at 3 and 9 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

1,200

Conditions

Human Papillomavirus Infection

Interventions

Enhancing Accessibility to Health CareOTHER

Receive enhanced access to vaccination

Informational InterventionOTHER

Receive standard CDC information

Informational InterventionOTHER

Receive video narratives

Eligibility

Sex: ALLMin age: 18 YearsMax age: 26 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-26 years. This criterion is based on the CDC recommendation of vaccination up to 26 years of age and the fact that individuals 18 years and older can consent by themselves for on-site vaccination * Ability to read and understand English * Self-identification as not yet having received any HPV vaccine injections. Self-identification is justified because it is safe to be vaccinated again, which could happen if a previously vaccinated person forgets their vaccination. Furthermore, in a person previously vaccinated with an older version of the vaccine, which targeted fewer HPV types, receiving the newer version would be advantageous and not cause any harm. Alternatives to self-identification, such as obtaining medical records from doctors' offices, would be very challenging for young adults, especially for those who do not remember when and where they might have received vaccination * Access to a smart phone, tablet or computer that is connected to the internet * Current enrollment in one of the participating schools with an anticipated continuous enrollment of at least 9 months Exclusion Criteria: * Being pregnant * Having a life-threatening allergy to any component of the HPV vaccine

Locations (1)

M D Anderson Cancer Center

Houston, Texas, United States

Outcomes

Primary Outcomes

Rate of human papillomavirus (HPV) vaccination initiation

Time frame: At 3 months

Rate of HPV vaccination completion

Time frame: At 9 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.